<DOC>
	<DOCNO>NCT02295930</DOCNO>
	<brief_summary>This phase II randomize study 4-months induction first-line chemotherapy FOLFOXIRI + cetuximab follow maintenance cetuximab bevacizumab patient affect KRAS wild type ( wt ) mCRC .</brief_summary>
	<brief_title>Induction Chemoterapy With Folfoxiri Plus Cetuxumab Unresectable Colorectal Cancer Patient</brief_title>
	<detailed_description>The aim study obtain rapid disease control therapy maximum tumoral shrinkage , treat patient less intensive maintenance inhibit tumoral regrowth .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma ; Availability formalinfixed paraffin embed tumor block primary and/or metastasis ; KRAS wildtype status primary colorectal cancer relate metastasis ; Unresectable measurable metastatic disease accord RECIST criterion ; Male female , age &gt; 18 year &lt; 75 year ; ECOG PS &lt; 2 age &lt; 71 year , ECOG PS = 0 aged 7175 year ; Life expectancy 3 month ; Adequate haematological function : ANC ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L , Hb ≥ 9 g/dL ; Adequate liver renal function : serum bilirubin ≤ 1.5 x ULN ; alkaline phosphatase transaminases ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) ; serum creatinine ≤ 1.5 x ULN ; Previous adjuvant chemotherapy contain oxaliplatin allow 12 month elapse end adjuvant therapy first relapse ; Previous adjuvant chemotherapy fluoropyrimidine monotherapy allow 6 month elapse end adjuvant first relapse ; At least 6 week prior extend radiotherapy 4 week surgery ; Written inform consent experimental treatment KRAS analysis . Prior palliative chemotherapy ; Prior treatment EGFR VEGF inhibitor ; Symptomatic peripheral neuropathy &gt; 2 grade NCICCTG criterion ; Presence history CNS metastasis ; Active uncontrolled infection ; active disseminate intravascular coagulation ; Past current history malignancy colorectal carcinoma , except curatively treat basal squamous cell carcinoma skin cancer situ carcinoma cervix ; Clinically significant cardiovascular disease : cerebrovascular accident myocardial infarction ≤ 12 month treatment start , unstable angina , NYHA ≥ grade 2 chronic heart failure , uncontrolled arrhythmia , uncontrolled hypertension ; Serious , nonhealing wound , ulcer , bone fracture ; Evidence bleed diathesis coagulopathy ; Major surgical procedure significant traumatic injury within 28 day prior study treatment start ; Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) ; Subtotal colectomy , malabsorption syndrome chronic inflammatory bowel disease ( i.e . ulcerative colitis , Chron syndrome ) ; Fertile woman ( &lt; 2 year last menstruation ) men childbearing potential willing use effective mean contraception . Psychiatric disorder preclude understanding information trial related topic , Serious underlie medical condition ( judged investigator ) could impair ability patient participate trial ( e.g . uncontrolled diabetes mellitus , active autoimmune disease ) Concurrent treatment experimental drug anticancer therapy ; treatment clinical trial within 30 day prior trial entry Definite contraindication use corticosteroid antihistamine premedication Known hypersensitivity trial drug hypersensitivity component trial drug Any concomitant drug contraindicate use trial drug accord product information pharmaceutical company Pregnancy Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Medical psychological condition , opinion investigator , would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>colorectal cancer ,</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>cetuximab</keyword>
	<keyword>folfoxiri</keyword>
	<keyword>kras wild type</keyword>
</DOC>